Madrigal Pharmaceuticals, Inc. (MDGL)
Summary
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Madrigal Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 24 | $6,929.68 | $12,988.01 | $6,058.33 | 87.43% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 20 | $11,646.8 | $10,823.34 | -$823.46 | -7.07% |
 Farallon Capital Farallon Capital Management LLC | 3,319 | $804,060.94 | $1.8M | $996,543.36 | 123.94% |
 John Paulson Paulson & Co. | 1.39M | $351.71M | $755.28M | $403.57M | 114.74% |
| CD Carine Duboscq Groupama Asset Managment | 35,238 | $12.89M | $19.12M | $6.23M | 48.35% |
Madrigal Pharmaceuticals, Inc. (MDGL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Madrigal Pharmaceuticals, Inc. ever had a stock split?
Madrigal Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | William J. Sibold CEO | NASDAQ (NGS) Exchange | 558868105 CUSIP |
| US Country | 915 Employees | 25 Jul 2016 Last Dividend | 25 Jul 2016 Last Split | 6 Feb 2007 IPO Date |
Overview
Madrigal Pharmaceuticals, Inc. is a forward-thinking clinical-stage biopharmaceutical company based in West Conshohocken, Pennsylvania. With a primary focus on addressing the significant unmet medical needs in non-alcoholic steatohepatitis (NASH), Madrigal Pharmaceuticals, Inc. is at the forefront of developing innovative therapeutic solutions. NASH, a more severe form of non-alcoholic fatty liver disease (NAFLD), is a major cause of liver disease worldwide, lacking effective FDA-approved treatments. This places Madrigal Pharmaceuticals in a critical position to potentially transform the treatment landscape for this challenging condition. The company’s commitment to pioneering research and clinical development underscores its dedication to improving patient outcomes in the NASH domain.
Products and Services
- Resmetirom
Madrigal Pharmaceuticals’ lead product candidate, resmetirom, is a testament to the company’s innovative approach in targeting complex liver diseases. Resmetirom is a liver-directed thyroid hormone receptor beta agonist specifically designed to address the root causes of NASH. The mechanism of action involves modulating liver fat metabolism, reducing liver fat, inflammation, and fibrosis, which are critical factors in the progression of NASH. Currently in Phase 3 clinical trials, resmetirom has shown promise in early studies, offering hope for a potential breakthrough therapy for patients suffering from this life-threatening condition. The ongoing research and development of resmetirom reflect Madrigal Pharmaceuticals’ dedication to scientific excellence and a patient-centered approach to healthcare.
